Effect of severe renal failure and haemodialysis on the pharmacokinetics of levosimendan and its metabolites

Clicks: 365
ID: 269372
2007
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Steady

Ranked #4 of 6 articles by views in clinical pharmacokinetics

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
The t(1/2) of the levosimendan metabolites was prolonged 1.5-fold and their AUC and C(max) were 2-fold in patients with severe CRF and ESRD patients undergoing haemodialysis as compared with healthy subjects. These results suggest that the dose should be reduced when levosimendan is used for the tre …
Reference Key
j2007clinicaleffect Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Puttonen J;Kantele S;Kivikko M;Häkkinen S;Harjola VP;Koskinen P;Pentikäinen PJ;;
Journal clinical pharmacokinetics
Year 2007
DOI
DOI not found
URL
https://www.ncbi.nlm.nih.gov/pubmed/17328582
Keywords
National Center for Biotechnology Information NCBI NLM MEDLINE humans pubmed abstract nih national institutes of health national library of medicine research support non-u.s. gov't algorithms female male aged middle aged Clinical Trial area under curve half-life phase i heart rate / physiology protein binding blood pressure / physiology kidney function tests kidney failure renal dialysis / adverse effects* hydrazones / adverse effects pyridazines / adverse effects simendan pmid:17328582 doi:10.2165/00003088-200746030-00004 jaakko puttonen sampo kantele pertti j pentikäinen biotransformation cardiotonic agents / adverse effects cardiotonic agents / pharmacokinetics* hydrazones / pharmacokinetics* chronic / metabolism* pyridazines / pharmacokinetics*

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.